Danny Nguyen, MD | Authors


Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC

January 18, 2022

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.